{'fraction_non_alphanumeric': 0.0692167577413479, 'fraction_numerical': 0.061930783242258654, 'mean_word_length': 3.90625, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of therapy on mature height in congenital adrenal hyperplasia.

The effects of therapy on the final height of children with congenital adrenal hyperplasia (CAH) were evaluated. Forty-six children with the 21-hydroxylase defect, 30 of whom had defects in electrolyte metabolism, were followed to maturity. In group A, there were 19 children (11 females and 8 males) who were diagnosed and adequately treated at less than 3 yr of age. In group B, there were 9 children (8 females and 1 male) who were adequately treated, but treatment was begun after 3 yr of age. In group C, there were 15 children (10 females and 5 males) whose treatment was inadequate. In group D, there were 3 female pseudohermaphrodites reared as males. The mean ages at diagnosis were: group A, 0.60 yr (±0.79 sd); group B, 6.43 yr (±2.96 sd); and group C, 4.96 yr (±5.19 sd). The group A males (final height, 171.9 cm ± 2.8 se) and females (final height, 162.5 cm ± 1.6 se) were significantly taller than the corresponding group C children (males, 160.14 cm ± 2.4 se, P < 0.01; females, 145.64 cm ± 2.89 se, P < ...